Ceretype Neuromedicine is a Cambridge, MA-based company that focuses on the practical application and integration of functional MRI (fMRI) in neuropsychiatric drug development and beyond. Led by CEO Emily Stern, the company’s platform makes targeted biomarkers accessible and delivers actionable evidence to improve drug discovery and patient care. Through its technical approach and its ability to sub-type and classify the human brain on a neurobiological level, Ceretype offers biologically-based therapeutic insights. The company closed its second round of seed financing with a $2M funding target that was oversubscribed. Ceretype intends to use the funds to help advance its fMRI platform. Investors in the round included Cedar Street Group as lead, along with Leafy Tunnel, The One Mind Accelerator and private investors.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2024